Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases

Chirayu M. Patel; Thaddeus J. Wadas; Yusuke Shiozawa

doi:10.3390/molecules26082162

Back

Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases

Journal article

Open access

Peer reviewed

Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases

Chirayu M. Patel, Thaddeus J. Wadas and Yusuke Shiozawa

Molecules (Basel, Switzerland), Vol.26(8), p.2162

04/01/2021

DOI: 10.3390/molecules26082162

PMCID: PMC8070008

PMID: 33918705

Files and links (1)

url

https://doi.org/10.3390/molecules26082162View

Published (Version of record) Open Access

Abstract

Bone metastasis remains a major cause of death in cancer patients, and current therapies for bone metastatic disease are mainly palliative. Bone metastases arise after cancer cells have colonized the bone and co-opted the normal bone remodeling process. In addition to bone-targeted therapies (e.g., bisphosphonate and denosumab), hormone therapy, chemotherapy, external beam radiation therapy, and surgical intervention, attempts have been made to use systemic radiotherapy as a means of delivering cytocidal radiation to every bone metastatic lesion. Initially, several bone-seeking beta-minus-particle-emitting radiopharmaceuticals were incorporated into the treatment for bone metastases, but they failed to extend the overall survival in patients. However, recent clinical trials indicate that radium-223 dichloride ((RaCl2)-Ra-223), an alpha-particle-emitting radiopharmaceutical, improves the overall survival of prostate cancer patients with bone metastases. This success has renewed interest in targeted alpha-particle therapy development for visceral and bone metastasis. This review will discuss (i) the biology of bone metastasis, especially focusing on the vicious cycle of bone metastasis, (ii) how bone remodeling has been exploited to administer systemic radiotherapies, and (iii) targeted radiotherapy development and progress in the development of targeted alpha-particle therapy for the treatment of prostate cancer bone metastasis.

Biochemistry & Molecular Biology

Chemistry

Chemistry, Multidisciplinary

Life Sciences & Biomedicine

Physical Sciences

Science & Technology

Details

Title: Subtitle: Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases
Creators: Chirayu M. Patel - Wake Forest University
Thaddeus J. Wadas - University of Iowa
Yusuke Shiozawa - Wake Forest University
Resource Type: Journal article
Publication Details: Molecules (Basel, Switzerland), Vol.26(8), p.2162
DOI: 10.3390/molecules26082162
PMID: 33918705
PMCID: PMC8070008
NLM abbreviation: Molecules
ISSN: 1420-3049
eISSN: 1420-3049
Publisher: Mdpi
Number of pages: 18
Grant note: W81XWH-17-1-0541; W81XWH-19-1-0045; W81XWH-19-1-0046 / U.S. Department of Defense; United States Department of Defense P30-CA012197 / National Cancer Institute's Cancer Center Support Grant Wake Forest Baptist Comprehensive Cancer Center Internal Pilot Funding R01-CA238888; R44-CA203184; R21-CA227709 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) METAvivor (METAvivor Research Award)
Language: English
Date published: 04/01/2021
Academic Unit: Radiology; Radiation Oncology
Record Identifier: 9984312983002771

Metrics

6 Record Views

6 Times Cited - Web of Science